Sunesis Pharmaceuticals Inc. [NASDAQ: SNSS] gained 24.00% on the last trading session, reaching $1.86 price per share at the time. The company report on December 1, 2020 that SHAREHOLDER ALERT: WeissLaw LLP Investigates Sunesis Pharmaceuticals, Inc.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sunesis Pharmaceuticals, Inc. (“Sunesis ” or the “Company”) (NASDAQ: SNSS) in connection with the Company’s proposed merger with privately-held Viracta Therapeutics, Inc. (“Viracta”). Under the terms of the merger agreement, Sunesis and Viracta will combine, resulting in current Viracta stockholders owning 86% of the post-close company and leaving only 14% of the surviving entity to current Sunesis stockholders. The combined company will operate under the name Viracta Therapeutics, Inc. and will continue to trade on the NASDAQ under the new ticker symbol “VIRX.”.
If you own Sunesis shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:.
Sunesis Pharmaceuticals Inc. represents 15.93 million in outstanding shares, while the company has a total market value of $31.62 million with the latest information. SNSS stock price has been found in the range of $1.77 to $2.07.
If compared to the average trading volume of 902.61K shares, SNSS reached a trading volume of 14196572 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Sunesis Pharmaceuticals Inc. [SNSS]:
Oppenheimer have made an estimate for Sunesis Pharmaceuticals Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on June 24, 2020. While these analysts kept the previous recommendation, Wells Fargo dropped their target price from $3 to $1. The new note on the price target was released on March 11, 2020, representing the official price target for Sunesis Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Sunesis Pharmaceuticals Inc. is set at 0.13, with the Price to Sales ratio for SNSS stock in the period of the last 12 months amounting to 14.37. The Price to Book ratio for the last quarter was 1.56, with the Price to Cash per share for the same quarter was set at 1.53.
Trading performance analysis for SNSS stock
Sunesis Pharmaceuticals Inc. [SNSS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 46.46. With this latest performance, SNSS shares gained by 58.97% in over the last four-week period, additionally sinking by -49.73% over the last 6 months – not to mention a drop of -56.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNSS stock in for the last two-week period is set at 80.62, with the RSI for the last a single of trading hit 87.38, and the three-weeks RSI is set at 67.54 for Sunesis Pharmaceuticals Inc. [SNSS]. The present Moving Average for the last 50 days of trading for this stock 1.3067, while it was recorded at 1.4800 for the last single week of trading, and 3.5033 for the last 200 days.
Sunesis Pharmaceuticals Inc. [SNSS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Sunesis Pharmaceuticals Inc. [SNSS] shares currently have an operating margin of -1123.40. Sunesis Pharmaceuticals Inc.’s Net Margin is presently recorded at -1125.42.
Return on Total Capital for SNSS is now -103.01, given the latest momentum, and Return on Invested Capital for the company is -146.69. Return on Equity for this stock declined to -147.96, with Return on Assets sitting at -88.77. When it comes to the capital structure of this company, Sunesis Pharmaceuticals Inc. [SNSS] has a Total Debt to Total Equity ratio set at 22.81. Additionally, SNSS Total Debt to Total Capital is recorded at 18.57, with Total Debt to Total Assets ending up at 16.87. Long-Term Debt to Equity for the company is recorded at 1.72, with the Long-Term Debt to Total Capital now at 0.80.
Reflecting on the efficiency of the workforce at the company, Sunesis Pharmaceuticals Inc. [SNSS] managed to generate an average of -$972,083 per employee.Sunesis Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.
Sunesis Pharmaceuticals Inc. [SNSS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Sunesis Pharmaceuticals Inc. posted -0.5/share EPS, while the average EPS was predicted by analysts to be reported at -0.74/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 32.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SNSS.
An analysis of insider ownership at Sunesis Pharmaceuticals Inc. [SNSS]
There are presently around $10 million, or 42.90% of SNSS stock, in the hands of institutional investors. The top three institutional holders of SNSS stocks are: BVF INC/IL with ownership of 1,727,308, which is approximately 565.647% of the company’s market cap and around 0.11% of the total institutional ownership; AISLING CAPITAL MANAGEMENT LP, holding 1,010,000 shares of the stock with an approximate value of $1.88 million in SNSS stocks shares; and NANTAHALA CAPITAL MANAGEMENT, LLC, currently with $1.29 million in SNSS stock with ownership of nearly -27.703% of the company’s market capitalization.
Positions in Sunesis Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 13 institutional holders increased their position in Sunesis Pharmaceuticals Inc. [NASDAQ:SNSS] by around 1,841,530 shares. Additionally, 26 investors decreased positions by around 463,853 shares, while 5 investors held positions by with 2,842,487 shares. The mentioned changes placed institutional holdings at 5,147,870 shares, according to the latest SEC report filing. SNSS stock had 4 new institutional investments in for a total of 63,599 shares, while 16 institutional investors sold positions of 73,434 shares during the same period.